{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T03:38:22Z","timestamp":1783481902561,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T00:00:00Z","timestamp":1525219200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11657-018-0444-6","type":"journal-article","created":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T22:29:25Z","timestamp":1525213765000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term benefits and risks of parathyroid hormone treatment in compliant osteoporotic patients. A Danish national register based cohort study"],"prefix":"10.1007","volume":"13","author":[{"given":"Anne-Luise","family":"Thorsteinsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vestergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Eiken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,2]]},"reference":[{"key":"444_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","volume":"126","author":"M McClung","year":"2013","unstructured":"McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM (2013) Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 126:13\u201320","journal-title":"Am J Med"},{"key":"444_CR2","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441","journal-title":"N Engl J Med"},{"key":"444_CR3","doi-asserted-by":"publisher","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","volume":"146","author":"SL Greenspan","year":"2007","unstructured":"Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB, Treatment of Osteoporosis with Parathyroid Hormone Study Group (2007) Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 146:326\u2013339","journal-title":"Ann Intern Med"},{"key":"444_CR4","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00198-004-1713-3","volume":"16","author":"JM Kaufman","year":"2005","unstructured":"Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, Lindsay R, Mitlak BH (2005) Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 16:510\u2013516","journal-title":"Osteoporos Int"},{"key":"444_CR5","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","volume":"357","author":"KG Saag","year":"2007","unstructured":"Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028\u20132039","journal-title":"N Engl J Med"},{"key":"444_CR6","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00198-013-2284-y","volume":"24","author":"S Silverman","year":"2013","unstructured":"Silverman S, Miller P, Sebba A, Weitz M, Wan X, Alam J, Masica D, Taylor KA, Ruff VA, Krohn K (2013) The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results. Osteoporos Int 24:2309\u20132317","journal-title":"Osteoporos Int"},{"key":"444_CR7","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1080\/01926230490462138","volume":"32","author":"JL Vahle","year":"2004","unstructured":"Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M (2004) Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 32:426\u2013438","journal-title":"Toxicol Pathol"},{"key":"444_CR8","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00198-013-2470-y","volume":"25","author":"UC Bang","year":"2014","unstructured":"Bang UC, Hyldstrup L, Jensen JE (2014) The impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers. Osteoporos Int 25:639\u2013644","journal-title":"Osteoporos Int"},{"key":"444_CR9","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1002\/jbmr.1768","volume":"27","author":"EB Andrews","year":"2012","unstructured":"Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, Masica D (2012) The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res 27:2429\u20132437","journal-title":"J Bone Miner Res"},{"key":"444_CR10","first-page":"200","volume":"13","author":"G Caggiari","year":"2016","unstructured":"Caggiari G, Leali PT, Mosele GR, Puddu L, Badessi F, Doria C (2016) Safety and effectiveness of teriparatide vs alendronate in postmenopausal osteoporosis: a prospective non randomized clinical study. Clin Cases Miner Bone Metab 13:200\u2013203","journal-title":"Clin Cases Miner Bone Metab"},{"key":"444_CR11","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2147\/CIA.S107285","volume":"11","author":"A Nishikawa","year":"2016","unstructured":"Nishikawa A, Ishida T, Taketsuna M, Yoshiki F, Enomoto H (2016) Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report. Clin Interv Aging 11:913\u2013925","journal-title":"Clin Interv Aging"},{"key":"444_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/IJWH.S4919","volume":"2","author":"A Sikon","year":"2010","unstructured":"Sikon A, Batur P (2010) Profile of teriparatide in the management of postmenopausal osteoporosis. Int J Womens Health 2:37\u201344","journal-title":"Int J Womens Health"},{"key":"444_CR13","first-page":"499","volume":"2","author":"D Bodenner","year":"2007","unstructured":"Bodenner D, Redman C, Riggs A (2007) Teriparatide in the management of osteoporosis. Clin Interv Aging 2:499\u2013507","journal-title":"Clin Interv Aging"},{"key":"444_CR14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00774-013-0546-6","volume":"32","author":"T Yamamoto","year":"2014","unstructured":"Yamamoto T, Taketsuna M, Guo X, Sato M, Sowa H (2014) The safety and effectiveness profile of daily teriparatide in a prospective observational study in Japanese patients with osteoporosis at high risk for fracture: interim report. J Bone Miner Metab 32:699\u2013708","journal-title":"J Bone Miner Metab"},{"key":"444_CR15","unstructured":"Sundhedsdatastyrelsen Cancerregisteret, Om de nationale sundhedsregistre. (2017) \n                    http:\/\/sundhedsdatastyrelsen.dk\/da\/registre-og-services\/om-de-nationale-sundhedsregistre\/sygedomme-laegemidler-og-behandlinger\/cancerregisteret"},{"key":"444_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373\u2013383","journal-title":"J Chronic Dis"},{"key":"444_CR17","unstructured":"L\u00e6gemiddelstyrelsen Vejledende kriterier for enkelttilskud\u2014teriparatide (2017) \n                    https:\/\/laegemiddelstyrelsen.dk\/da\/tilskud\/individuelle-tilskud\/enkelttilskud\/vejledende-kriterier\/osteoporose-forsteo\/"},{"key":"444_CR18","unstructured":"L\u00e6gemiddelstyrelsen Vejledende kriterier for enkelttilskud\u2014bisfosfonater (2017) \n                    https:\/\/laegemiddelstyrelsen.dk\/da\/tilskud\/individuelle-tilskud\/enkelttilskud\/vejledende-kriterier\/osteoporose-bisfosfonater,-denosumab-og-raloxifen\/"},{"key":"444_CR19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1359\/JBMR.041214","volume":"20","author":"PD Delmas","year":"2005","unstructured":"Delmas PD, van de Langerijt L, Watts NB, Eastell R, Genant H, Grauer A, Cahall DL, IMPACT Study Group (2005) Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res 20:557\u2013563","journal-title":"J Bone Miner Res"},{"key":"444_CR20","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1007\/s00198-014-3003-z","volume":"26","author":"EB Andrews","year":"2015","unstructured":"Andrews EB, Gilsenan AW, Midkiff KD, Harris DH (2015) Comments on bang et al.: the impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers. Osteoporos Int 26:1663\u20131664","journal-title":"Osteoporos Int"},{"key":"444_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00223-016-0143-5","volume":"99","author":"BL Langdahl","year":"2016","unstructured":"Langdahl BL, Ljunggren O, Benhamou CL, Marin F, Kapetanos G, Kocjan T, Lespessailles E, Napoli N, Nikolic T, Petto H, Moll T, Lindh E (2016) Fracture rate, quality of life and back pain in patients with osteoporosis treated with teriparatide: 24-month results from the Extended Forsteo Observational Study (ExFOS). Calcif Tissue Int 99:259\u2013271","journal-title":"Calcif Tissue Int"},{"key":"444_CR22","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s00223-009-9299-6","volume":"85","author":"BL Langdahl","year":"2009","unstructured":"Langdahl BL, Rajzbaum G, Jakob F, Karras D, Ljunggren O, Lems WF, Fahrleitner-Pammer A, Walsh JB, Barker C, Kutahov A, Marin F (2009) Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 85:484\u2013493","journal-title":"Calcif Tissue Int"},{"key":"444_CR23","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.2165\/0003495-200868180-00012","volume":"68","author":"SK Blick","year":"2008","unstructured":"Blick SK, Dhillon S, Keam SJ (2008) Teriparatide: a review of its use in osteoporosis. Drugs 68:2709\u20132737","journal-title":"Drugs"},{"key":"444_CR24","unstructured":"European Medicines Agency Summary of product characteristics. (2017)"},{"key":"444_CR25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.17219\/acem\/42626","volume":"25","author":"A Jodkowska","year":"2016","unstructured":"Jodkowska A, Tupikowski K, Szymczak J, Bohdanowicz-Pawlak A, Bolanowski M, Bednarek-Tupikowska G (2016) Interdisciplinary aspects of primary hyperparathyroidism: symptomatology in a series of 100 cases. Adv Clin Exp Med 25:285\u2013293","journal-title":"Adv Clin Exp Med"},{"key":"444_CR26","doi-asserted-by":"publisher","first-page":"112","DOI":"10.14712\/23362936.2015.50","volume":"116","author":"P Broulik","year":"2015","unstructured":"Broulik P, Adamek S, Libansky P, Kubinyi J (2015) Changes in the pattern of primary hyperparathyroidism in Czech Republic. Prague Med Rep 116:112\u2013121","journal-title":"Prague Med Rep"},{"key":"444_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/dmrr.199","volume":"17","author":"WH Taylor","year":"2001","unstructured":"Taylor WH, Khaleeli AA (2001) Coincident diabetes mellitus and primary hyperparathyroidism. Diabetes Metab Res Rev 17:175\u2013180","journal-title":"Diabetes Metab Res Rev"},{"key":"444_CR28","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1007\/s00198-010-1498-5","volume":"22","author":"A Fahrleitner-Pammer","year":"2011","unstructured":"Fahrleitner-Pammer A, Langdahl BL, Marin F, Jakob F, Karras D, Barrett A, Ljunggren O, Walsh JB, Rajzbaum G, Barker C, Lems WF (2011) Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporos Int 22:2709\u20132719","journal-title":"Osteoporos Int"},{"key":"444_CR29","first-page":"173","volume":"11","author":"R Vellucci","year":"2014","unstructured":"Vellucci R, Mediati RD, Ballerini G (2014) Use of opioids for treatment of osteoporotic pain. Clin Cases Miner Bone Metab 11:173\u2013176","journal-title":"Clin Cases Miner Bone Metab"},{"key":"444_CR30","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1210\/jc.2012-1027","volume":"97","author":"S Khosla","year":"2012","unstructured":"Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D, Potts JT (2012) Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 97:2272\u20132282","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11657-018-0444-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-018-0444-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-018-0444-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T00:01:08Z","timestamp":1556755268000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11657-018-0444-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,2]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["444"],"URL":"https:\/\/doi.org\/10.1007\/s11657-018-0444-6","relation":{},"ISSN":["1862-3522","1862-3514"],"issn-type":[{"value":"1862-3522","type":"print"},{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,2]]},"assertion":[{"value":"4 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by Statistics Denmark and controlled by the Danish Data Protection Agency. Approval from the Regional Committee on Biomedical Research Ethics is not required for registered studies in Denmark.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AT has received a grant from Eli Lilly. PV has received unrestricted research grants from Servier and MSD Denmark and travel grants from Amgen, MSD, Eli Lilly, Novartis, and Servier. PE is an advisory board member of Eli Lilly, MSD, and Amgen and has received lecture fees from Eli Lilly and Amgen. LH has received grants from MSD Denmark and has received speaker fees from both MSD Denmark and Eli Lilly.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"50"}}